GlassScriptPhysician profile
Angie Harden
NPI 1942727060
$1,998.31
in general payments reported to CMS, 2019-2025
32 companies · $30.00 in 2025
The $30.00 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,492 · 2022: $226 · 2023: $101 · 2024: $149 · 2025: $30.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $354.47 | 2021-2022 | |
| Amgen INC. | $179.33 | 2021 | |
| Abbvie INC. | $157.84 | 2022-2024 | |
| Seagen INC. | $142.32 | 2021-2022 | |
| Gilead Sciences, INC. | $123.18 | 2023-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $103.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $94.17 | 2021 | |
| Astellas Pharma US INC | $79.92 | 2021-2023 | Padcev |
| Genzyme Corporation | $78.76 | 2021 | |
| Incyte Corporation | $70.72 | 2021 | |
| Daiichi Sankyo INC. | $64.48 | 2021 | |
| Foundation Medicine, INC. | $60.16 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $56.84 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $50.02 | 2021 | |
| Kite Pharma, INC. | $37.75 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $35.48 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.62 | 2021 | |
| Dova Pharmaceuticals | $31.86 | 2021 | |
| Glaxosmithkline, LLC. | $24.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.08 | 2021 | |
| Array Biopharma INC | $19.90 | 2021 | |
| Lilly USA, LLC | $19.69 | 2021 | |
| Pfizer INC. | $19.26 | 2021 | |
| Puma Biotechnology, INC. | $18.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.92 | 2024 | |
| Celgene Corporation | $17.27 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.80 | 2021 | |
| Servier Pharmaceuticals LLC | $14.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.18 | 2021 | |
| Blueprint Medicines Corporation | $13.87 | 2021 | |
| Agios Pharmaceuticals, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angie Harden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.